VTYX
NASDAQ · Pharmaceuticals
Ventyx Biosciences Inc
$14.00
+0.02 (+0.14%)
Financial Highlights (FY 2025)
Revenue
27.43M
Net Income
6.42M
Gross Margin
34.3%
Profit Margin
23.4%
Rev Growth
-7.8%
D/E Ratio
0.43
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 34.3% | 34.3% | 34.3% |
| Operating Margin | 24.8% | 23.4% | 23.4% |
| Profit Margin | 23.4% | 19.0% | 22.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.43M | 24.73M | 29.85M |
| Gross Profit | 9.41M | 8.48M | 10.24M |
| Operating Income | 6.80M | 5.79M | 6.98M |
| Net Income | 6.42M | 4.69M | 6.83M |
| Gross Margin | 34.3% | 34.3% | 34.3% |
| Operating Margin | 24.8% | 23.4% | 23.4% |
| Profit Margin | 23.4% | 19.0% | 22.9% |
| Rev Growth | -7.8% | +2.8% | +7.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 281.50M | 285.21M | 345.58M |
| Total Equity | 652.99M | 597.53M | 612.82M |
| D/E Ratio | 0.43 | 0.48 | 0.56 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.71M | 7.29M | 9.18M |
| Free Cash Flow | 5.17M | 5.81M | 4.69M |